Trial Profile

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Acronyms DESTINY-Lung06
Sponsors Daiichi Sankyo Company

31 Oct 2025 According to Daiichi Sankyo media release, The first patient has been dosed in the DESTINY-Lung06phase 3 trial.
22 Sep 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 7 Sep 2025 to 7 Oct 2025.
22 Sep 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com